An Economic Evaluation of Ranibizumab versus Aflibercept for the treatment of Neovascular (WET) AMD in the United Kingdom

W.A. Malcolm, L. Claxton, Robert Hodgson, Matthew Taylor

Research output: Contribution to journal › Article

doi: 10.1016/j.jval.2015.03.1057

Access to Document

@article{1f8d124dbb2a436f914a9db655f30396,

title = "An Economic Evaluation of Ranibizumab versus Aflibercept for the treatment of Neovascular (WET) AMD in the United Kingdom",

author = "W.A. Malcolm and L. Claxton and Robert Hodgson and Matthew Taylor",

note = "doi: 10.1016/j.jval.2015.03.1057",

year = "2015",

doi = "10.1016/j.jval.2015.03.1057",

language = "English",

volume = "18",

pages = "A183",

journal = "Value in Health",

issn = "1098-3015",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - An Economic Evaluation of Ranibizumab versus Aflibercept for the treatment of Neovascular (WET) AMD in the United Kingdom

AU - Malcolm, W.A.

AU - Claxton, L.

AU - Hodgson, Robert

AU - Taylor, Matthew

N1 - doi: 10.1016/j.jval.2015.03.1057

PY - 2015

Y1 - 2015

U2 - 10.1016/j.jval.2015.03.1057

DO - 10.1016/j.jval.2015.03.1057

M3 - Article

SN - 1098-3015

VL - 18

SP - A183

JO - Value in Health

JF - Value in Health

IS - 3

ER -